CHRS Overview
Upcoming Projects (CHRS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CHRS)
-
Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Tickers: CHRS, OTLK
Executed On: Mar 17, 2023 at 12:00 PM EDT -
A Second look at the differences between Cimerli anti-VEGF vs Lucentis as therapy for Wet-AMD
Tickers: CHRS, RHHBY
Executed On: Sep 09, 2022 at 12:30 PM EDT -
A First look at the differences between Cimerli anti-VEGF vs Lucentis as therapy for Wet-AMD
Ticker: CHRS
Executed On: Sep 02, 2022 at 01:00 PM EDT
Upcoming & Overdue Catalysts (CHRS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CHRS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
